NDAORALTABLETPriority Review
Approved
Jan 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
11
Mechanism of Action
Sodium Channel Antagonists
Pharmacologic Class:
Sodium Channel Blocker
Clinical Trials (5)
Suzetrigine for Non-Mastectomy Breast Surgery
Started Mar 2026
120 enrolled
Pain, Acute PostoperativeBreast Disease
Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
Started Feb 2026
12 enrolled
Pain
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Started Nov 2025
734 enrolled
Diabetic Peripheral Neuropathic Pain
A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries
Started Mar 2025
47 enrolled
Acute Pain
A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries
Started Mar 2025
100 enrolled
Acute Pain
Loss of Exclusivity
LOE Date
Dec 4, 2040
179 months away
Patent Expiry
Dec 4, 2040
Exclusivity Expiry
Jan 30, 2030
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 11834441 | Dec 4, 2040 | SubstanceProduct | U-4125 |